BHVN

$BHVN Every day now 13.90-14.50.

$BHVN Nice finish for the day--I read the below post mentioning RBC and Piper. They are not putting the Obesity drug into their models as it is Phase 2 and a wild card. However, make no mistake if they meet or get close to the Lilly Drug's Efficiency "bimagrumab" without the side effects--they have the makings of a blockbuster. Biohaven’s Senior VP of Clinical Development, Peter Ackerman, explicitly stated that achieving "bimagrumab-like efficacy" is their exact target. Weight Loss+ Retaining Muscle Mass in a Single Drug = $$$$. Holding. Like even the company says it is going to be a big H2.

RBC Capital y'day⬆️ $BHVN's PT to $23 from $22 and reiterated Outperform after BHVN reported their 2Q26 earnings, with all programs largely on track. $XENE $RAPP PRAX ABBV ARWR - SRPT WVE RBC Capital said -- Despite Kv7 being the near-term catalyst, investor focus has largely been on troriluzole's potential return (no concrete action in today's release), and looking further ahead to the degrader data given what we est. as a >$4B oppt'y by 2035. Still, we think the near-term Kv7 readout is more likely than not to succeed, and our work suggests there is room in the market for multiple agents in the class. While spend remains somewhat elevated, we think the pipeline is attractive on a PoS adjusted basis, and we remain buyers into year-end. PT to $23 on model updates.

$BHVN Company is using the 350M ATM--As of December 31, 2025: The company had 132.7 million shares out in the hands of the public.As of June 30, 2026: Six months later, that number jumped to 151.0 million shares. This text officially proves that the company printed and sold exactly 18,242,418 new common shares to open-market investors during the first half of 2026 to bring in cash. https://www.prnewswire.com/news-releases/biohaven-reports-recent-business-developments-and-second-quarter-2026-financial-results-302847335.html

$BHVN nothing burger

$BHVN Earlier Relase March 19---Obesity Phase 2 Trial: On March 19, 2026, Biohaven issued a PR confirming full enrollment in its 150-patient proof-of-concept study. This trial evaluates once-weekly and once-monthly subcutaneous dosing as a monotherapy. Topline data is expected to be released in the second half of 2026.--But the new PR doesn't mention Topline? Wouldn't that be a massive change?

$BHVN Did they change the obesity read out? Completed enrollment in Phase 2 obesity study with taldefgrobep alfa. Then in upcoming milestones--Completed enrollment in Phase 2 study in obesity in 1Q 2026. They were supposed to read out Topline in 2026, what is going on or am I missing something?

$BHVN Why the drop? The earnings we just a corporate update on programs. I don't see anything new.

@Ccg_ not abnormal for $BHVN

$BHVN seeing a close in the 15s today gang

$BHVN this setup seems odd. Last day to announce earnings and they haven’t even announced a call. Either partnership or massive solution coming.